会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • REAGENTS FOR THE DETECTION OF PROTEIN PHOSPHORYLATION IN LEUKEMIA SIGNALING PATHWAYS
    • 用于检测白血病信号途径中蛋白质磷酸化的试剂
    • WO2007027957A3
    • 2009-01-29
    • PCT/US2006034126
    • 2006-08-30
    • CELL SIGNALING TECHNOLOGY INCPOLAKIEWICZ ROBERTOGOSS VALERIELEE KIMBERLYGU TING-LEIMORITZ ALBRECHT
    • POLAKIEWICZ ROBERTOGOSS VALERIELEE KIMBERLYGU TING-LEIMORITZ ALBRECHT
    • G01N33/53C07K16/00G01N33/573
    • G01N33/57426C07B59/008C07K16/3061C07K16/44G01N33/6803G01N33/6842G01N2333/9121
    • The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.
    • 本发明公开了在信号转导蛋白中识别的近480个新的磷酸化位点和人类白血病的途径,并提供磷酸化位点特异性抗体和重同位素标记肽(AQUA肽),用于选择性检测和定量这些磷酸化位点/蛋白质,如 以及使用试剂用于此目的的方法。 鉴定的磷酸化位点是发生在以下蛋白质类型中的位点:衔接子/支架蛋白,乙酰转移酶,肌动蛋白结合蛋白,粘附蛋白,凋亡蛋白,钙结合蛋白,细胞周期调节蛋白,细胞表面蛋白,通道蛋白,伴侣蛋白 鸟嘌呤核苷酸交换因子,解旋酶蛋白,免疫球蛋白超家族蛋白,抑制蛋白,蛋白激酶,脂质激酶,连接酶,脂质结合蛋白,甲基转移酶,运动蛋白,肌动蛋白, 氧化还原酶,磷酸二酯酶,磷脂酶,蛋白酶,受体蛋白,trascription因子,转移酶,翻译/转运蛋白和泛素缀合系统蛋白。
    • 3. 发明申请
    • REAGENTS FOR THE DETECTION OF PROTEIN PHOSPHORYLATION IN LEUKEMIA SIGNALING PATHWAYS
    • 用于检测白血病信号通路中的蛋白质磷酸化的试剂
    • WO2007027957A9
    • 2007-05-31
    • PCT/US2006034126
    • 2006-08-30
    • CELL SIGNALING TECHNOLOGY INCPOLAKIEWICZ ROBERTOGOSS VALERIELEE KIMBERLYGU TING-LEIMORITZ ALBRECHT
    • POLAKIEWICZ ROBERTOGOSS VALERIELEE KIMBERLYGU TING-LEIMORITZ ALBRECHT
    • G01N33/574
    • G01N33/57426C07B59/008C07K16/3061C07K16/44G01N33/6803G01N33/6842G01N2333/9121
    • The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.
    • 本发明公开了在人白血病的信号转导蛋白和通路中鉴定的近480个新的磷酸化位点,并提供用于选择性检测和定量这些磷酸化位点/蛋白的磷酸化位点特异性抗体和重同位素标记肽(AQUA肽),如 以及为此目的使用试剂的方法。 在鉴定的磷酸化位点中,有以下蛋白质类型发生的位点:衔接子/支架蛋白质,乙酰转移酶,肌动蛋白结合蛋白,粘附蛋白,凋亡蛋白,钙结合蛋白,细胞周期调节蛋白,细胞表面蛋白,通道蛋白,伴侣蛋白 ,收缩蛋白,细胞因子蛋白,细胞骨架蛋白,G蛋白调节剂和GTP酶活化蛋白,鸟嘌呤核苷酸交换因子,解旋酶蛋白,免疫球蛋白超家族蛋白,抑制蛋白,蛋白激酶,脂质激酶,连接酶,脂质结合蛋白,甲基转移酶, 氧化还原酶,磷酸酶,磷酸二酯酶,磷脂酶,蛋白酶,受体蛋白,转录因子,转移酶,翻译/转运蛋白和泛素缀合系统蛋白。
    • 4. 发明申请
    • REAGENTS FOR THE DETECTION OF PROTEIN PHOSPHORYLATION IN LEUKEMIA SIGNALING PATHWAYS
    • 用于检测白血病信号通道中蛋白质磷酸化的试剂
    • WO2007064743A8
    • 2008-09-04
    • PCT/US2006045760
    • 2006-11-29
    • CELL SIGNALING TECHNOLOGY INCPOLAKIEWICZ ROBERTOLEE KIMBERLYGU TING-LEIGOSS VALERIE
    • POLAKIEWICZ ROBERTOLEE KIMBERLYGU TING-LEIGOSS VALERIE
    • C12N9/00
    • G01N33/57426
    • La présente invention a trait à presque 123 nouveaux sites de phosphorylation identifiés dans des protéines de transduction de signal et de voies sous-jacentes de la leucémie humaine, et fournit des anticorps spécifiques de sites de phosphorylation et de peptides étiquetés d'isotopes lourds (peptides AQUA) pour la détection sélective et la quantification de ces sites/protéines phosphorylés, ainsi que des procédés d'utilisation des réactifs à cette fin. Parmi les sites de phosphorylation identifiés se trouvent des sites présents dans les types de protéines suivants: des protéines kinases, des protéines adaptatrices/squelettiques, la phosphatase/phospholipases, les protéines G/de protéines d'activation de la GTPase /des facteurs d'échange de nucléotides à guanine, des enzymes de métabolisme cellulaire, des protéines de liaison à l'ARN, des protéines de transcription, des protéines complexes d'initiation de traduction, des transférases, des protéines du système de conjugaison d'ubiquitine, des protéines vésiculaires, des protéines de liaison à l'actine, des protéines de l'apoptose, des protéines de chimiokine, des protéines matricielles extracellulaires de protéines enzymatiques, des hélicases, des hydrolases, des protéines de la superfamille d'immunoglobulines, des protéines inhibitrices, des isomérases, des ligases, des protéines de liaison aux lipides, des méthyltransférases, des protéines motrices, des protéines réceptrices, et des protéines chaperones.
    • 6. 发明申请
    • MUTANT JAK3 KINASE IN HUMAN LEUKEMIA
    • MUTANT JAK3激活人类LEUKEMIA
    • WO2007084630A2
    • 2007-07-26
    • PCT/US2007001359
    • 2007-01-19
    • CELL SIGNALING TECHNOLOGY INCGOSS VALERIEGU TING-LEIPOLAKIEWICZ ROBERTODRUKER BRIANWALTERS DENISE
    • GOSS VALERIEGU TING-LEIPOLAKIEWICZ ROBERTODRUKER BRIANWALTERS DENISE
    • C12N9/12
    • C12N9/1205C12Q1/6886C12Q2600/106C12Q2600/136
    • In accordance with the invention, a novel activating mutation (alanine 572 to valine) in JAK3 kinase has been discovered in human acute myelogenous leukemia (AML). The mutant JAK3 kinase was confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant JAK3 kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the mutant polypeptides. The disclosed identification of this new mutant protein and enables new methods for determining the presence of mutant JAK3 kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the mutant proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
    • 根据本发明,已经在人急性骨髓性白血病(AML)中发现JAK3激酶中的新的活化突变(丙氨酸572至缬氨酸)。 证实突变体JAK3激酶能够驱动急性巨核细胞白血病(AML-M7)的增殖和存活。 因此,本发明部分地提供分离的多核苷酸和编码所公开的突变体JAK3激酶多肽的载体,用于检测其的探针,分离的突变多肽,重组多肽和用于检测突变多肽的试剂。 所公开的这种新突变蛋白质的鉴定,并且使得能够确定生物样品中突变体JAK3激酶多肽的存在的新方法,用于筛选抑制突变蛋白质的化合物的方法,以及抑制以突变体为特征的癌症进展的方法 多核苷酸或多肽,其也由本发明提供。
    • 7. 发明申请
    • TRANSLOCATION AND MUTANT CSF1R KINASE IN HUMAN LEUKEMIA
    • 人淋巴细胞转移和突变CSF1R激酶
    • WO2007075933A2
    • 2007-07-05
    • PCT/US2006048867
    • 2006-12-21
    • CELL SIGNALING TECHNOLOGY INCGU TING-LEIGOSS VALERIEPOLAKIEWICZ ROBERTODRUKER BRIANWALTERS DENISE
    • GU TING-LEIGOSS VALERIEPOLAKIEWICZ ROBERTODRUKER BRIANWALTERS DENISE
    • C07K14/705
    • C12N9/12C07K2319/85
    • In accordance with the invention, a novel gene translocation, (3p21 , 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1 R) kinase has now been identified. The RBM6-CSF1 R fusion protein and truncated CSF1R kinase itself, which both retain CSF1 R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant CSF 1 R kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
    • 根据本发明,在人骨髓性白血病(AML)中的新型基因易位(3p21,5q33),其导致将部分RNA结合蛋白-6(RBM6)与巨噬细胞集落刺激因子-1受体(RBF6)结合的融合蛋白 CSF1R)激酶已被鉴定。 证实了RBM6-CSF1R融合蛋白和截短的CSF1R激酶本身都保留CSF1R酪氨酸激酶活性,以驱动急性巨核细胞白血病(AML-M7)的增殖和存活。 因此,本发明部分地提供分离的多核苷酸和编码所公开的突变型CSF1R激酶多肽的载体,用于检测其的探针,分离的突变多肽,重组多肽和用于检测融合和截短的多肽的试剂。 所公开的这种新的融合蛋白和截短的激酶的鉴定使得能够确定生物样品中这些突变型CSF1R激酶多肽的存在的新方法,用于筛选抑制蛋白质的化合物的方法,以及抑制癌症进展的方法 其特征在于突变体多核苷酸或多肽,其也由本发明提供。